All 2026 dates on sale. Register before December 31!
As GLP-1 therapies continue to evolve, December 2025 brought several updates relevant to your practice—from new drug options to coverage changes and real-world implementation insights. This update summarizes the most clinically relevant developments.
In this GLP-1 round up:
The FDA approved oral semaglutide (Wegovy pill) with efficacy comparable to the injectable version—16.6% weight loss vs. 15% for injectable Wegovy. The starting price is $149/month compared to $1,000+ for injectable Wegovy.
Action Item: Update your patient education materials to include oral option as first-line conversation point for appropriate patients.
The Centers for Medicare & Medicaid Services launched a new voluntary model combining manufacturer price negotiation with standardized coverage criteria. A separate Medicare GLP‑1 payment demonstration begins July 2026, under which eligible beneficiaries pay $50 per month for GLP‑1 medications.
North Carolina Medicaid reinstated GLP-1 coverage for 3.1 million beneficiaries (effective December 12, 2025). State criteria designate certain GLP‑1s as preferred and others as subject to additional prior‑authorization or step‑therapy requirements.
Broader insurance coverage increases public awareness and patient demand. More people know GLP-1s exist and are actively seeking weight loss solutions. This expands your patient pool.
Real-world outcomes suggest that patients receiving medication alone—without structured support—often struggle to maintain results long-term. Those who discontinue early or don’t reach therapeutic doses frequently face weight regain. This reality creates an opportunity for practices offering comprehensive support.
If you’re building or considering a direct-pay comprehensive care model, this expanded awareness is valuable. Patients seeking more than just a prescription—those looking for structured nutrition, exercise programming, behavioral support, and ongoing optimization—represent a distinct market segment willing to invest in lasting results.
For practices offering comprehensive programs, the positioning is straightforward: you provide the structured support system that makes medication effective. Insurance covers the medication; you provide the framework for sustainable outcomes.
For all practices, broader coverage means more patient inquiries. Some will be looking for medication only; others will be seeking comprehensive support. Understanding your practice model helps you identify which patients are the right fit.
Economic Validation: The Institute for Clinical and Economic Review (ICER)‘s final evidence report finds that injectable semaglutide, oral semaglutide, and tirzepatide each deliver substantial net health benefits over lifestyle changes alone and remain cost-effective at standard willingness-to-pay thresholds based on current net prices. Tirzepatide shows greater average weight loss than injectable semaglutide (rated “promising but inconclusive”), while oral semaglutide yields somewhat less (“comparable or worse”). In practice, all three qualify as high-impact; optimal choice depends on efficacy, safety, access, patient preferences, and your behavioral support system.
Eli Lilly’s retatrutide (TRIUMPH-4 trial) achieved up to 28.7% mean weight loss at 12 mg (vs 22.5% with tirzepatide/Zepbound), plus 75.8% knee OA pain reduction; note 18.2% discontinuation from GI/dysesthesia effects.
Trade-off: Higher discontinuation rates (18.2% high dose vs. 4% placebo) due to GI side effects and dysesthesia—requires careful patient selection and side effect management.
Eli Lilly’s orforglipron Phase III trial (ATTAIN-MAINTAIN) enabled injectable-to-oral transitions, preserving most weight loss over 52 weeks. This expands your treatment sequencing options.
Practical Considerations:
Action Items:
What the FDA Actually Requires: GLP-1 medications must be used with low-calorie diet and regular physical activity. Medication is not a standalone treatment.
Why This Matters for Your Business Model: Insurance rarely reimburses comprehensive lifestyle support. Patients willingly pay direct for programs delivering lasting results versus temporary prescription-only weight loss.
Your Opportunity: Look for programs like IAPAM’s Certified Medical Weight Management Provider™ (CWMP) pathway that incorporate FDA-mandated lifestyle support from day one. This positions trained practices as the premium alternative to commodity prescribers.
In addition to meeting FDA requirements, you are also building a business model around what actually works. The Clean Start Weight proven ketogenic/intermittent fasting protocol plus exercise programming plus behavioral support is not a commodity. It’s a system that produces results.
Important Context: These are hypothesis-generating findings requiring prospective, controlled trials before expanding clinical indications. Not yet applicable to clinical practice; stay informed but avoid off-label promotion.
December’s updates reflect the normal evolution of the GLP-1 field: new formulations, expanded coverage, and refined understanding of how to optimize outcomes. The oral pill approval is genuinely significant because it removes needle phobia and access barriers for many patients. Everything else is the ongoing work of matching the right treatment to the right patient and supporting them with comprehensive care. Practices that stay current on these developments and adapt their protocols accordingly will continue to deliver better outcomes.
The IAPAM’s Certified Medical Weight Management Provider™ (CWMP) program equips you with the protocols, patient-care strategies, and business tools to implement today’s GLP-1 and metabolic therapies effectively. You’ll learn how to integrate medications like tirzepatide, semaglutide, and Saxenda® into a holistic, sustainable program that prioritizes long-term outcomes.
Stay ahead of the science. Strengthen your systems. Empower your patients to succeed.
Explore the program and get the tools you need to build a sustainable, patient-first weight loss practice.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss.
Sources:
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!